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Abstract
Background
Apolipoprotein D (ApoD) has been proposed as a predictor of breast cancer recurrence
among estrogen receptor-positive (ER+), tamoxifen-treated patients.
Methods
We conducted a population-based case-control study nested in a population of 11,251
women aged 35–69 years at diagnosis with Stage I–III breast cancer between 1985 and
2001 on Denmark’s Jutland Peninsula and registered with the Danish Breast Cancer Coop-
erative Group. We identified 541 recurrent or contralateral breast cancers cases among
women with ER+ disease treated with tamoxifen for at least 1 year and 300 cases in women
with ER– disease never treated with tamoxifen. We matched one control subject per case
and assessed ApoD expression in the tumor cell nucleus and cytoplasm using tissue micro-
array immunohistochemistry. We computed the odds ratio (OR) associating ApoD expres-
sion with recurrence and adjusted for potential confounding using logistic regression.
Results
Cytoplasmic ApoD expression was seen in 68% of ER+ tumors, in 66% of ER– tumors, and
in 66% of controls across both groups. In women with ER+ tumors, the associations of cyto-
plasmic ApoD expression with recurrence (OR = 1.0; 95% CI = 0.7 to 1.4) and increasing
cytoplasmic expression with recurrence (OR = 1.0; 95% CI = 0.996 to 1.003) were null, as
were those for women with ER– tumors. Associations for nuclear ApoD expression and
combined nuclear and cytoplasmic expression were similarly near-null.
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Conclusion
ApoD expression is likely not a predictor of recurrence in tamoxifen-treated patients.
Impact
This study eliminates the previously suggested marker ApoD as a predictor of recurrence
among tamoxifen-treated women.
Introduction
Breast cancer accounts for the highest number of cancer cases among women worldwide, and
is the second leading cause of cancer death.[1, 2] Between two-thirds and three-quarters of
breast tumors express the estrogen-receptor-alpha (ERα) protein.[3, 4] Patients with ER
+ breast cancers usually receive adjuvant anti-estrogen therapy, typically tamoxifen—a selec-
tive ER modulator—or an aromatase inhibitor. [5–11] Tamoxifen selectively binds to the
ligand-binding domain of the ER, blocking estrogen’s ability to bind and induce proliferation
of the cancer cells.[12–14]
In spite of tamoxifen’s measurable positive effect on breast cancer prognosis, only about
70% of all ER+ breast cancers respond to anti-estrogen therapies.[12, 15] In addition, many
breast cancers that initially respond eventually develop resistance to these therapies.[16] Effec-
tive use of anti-estrogen therapy may depend on the ability to subtype receptor-positive breast
cancers based on their biomarker profiles.[15, 17–19] Despite a number of studies on the sub-
ject, to date, no biomarker has been translated into clinical practice to predict which tamoxi-
fen-treated patients are at high risk for recurrence.[20]
Apolipoprotein D (ApoD) expression may be predictive of recurrence among tamoxifen-
treated patients.[21–24] ApoD is a 29-kDa glycoprotein involved in transport of hydrophobic
ligands and is ubiquitous in human tissue.[25–27] Molecular studies have demonstrated an
inhibitory effect of the ER on ApoD, with up-regulation following tamoxifen treatment, likely
through blockage of ER activity.[28] As a result, combined ER positivity and ApoD positivity
could reflect a malfunctioning hormone receptor pathway, resulting in ineffective tamoxifen
treatment and a higher risk for relapse.[27–31] Only two studies have explored the direct rela-
tion between ApoD expression and recurrence among tamoxifen-treated patients.[26, 32] We
sought to examine precisely this association in a larger, well-characterized population.
Materials and methods
Patients
Using the Danish Breast Cancer Cooperative Group (DBCG) database, we collected informa-
tion on 11,251 female residents of the Jutland Peninsula between the ages of 35 and 69 who
were diagnosed with Stage I–III invasive breast cancer between 1985 and 2001.[33, 34] The
DBCG ends routine follow-up of breast cancer patients at ten years. For the purposes of this
study, data were collected beginning at one year after the date of diagnosis, and ending on the
date of a first breast cancer recurrence, death from any cause, loss to follow-up due to emigra-
tion, after ten years, or September 1, 2006 (the end of the study’s follow-up period) by linkage
to the Civil Registration System.[35, 36] All data were linked using Danish Personal Registra-
tion Numbers.
The role of ApoD in tamoxifen resistance
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Patients were divided into two subgroups—those whose tumors showed expression of ER
and who had been on tamoxifen therapy for at least one year, and those whose tumors did not
show expression of ER, were not treated with tamoxifen, and who had survived for at least one
year. All other patients were excluded, including patients who received neoadjuvant treatment,
though this was highly uncommon during the study period in Denmark.[37] Tumors were
considered ER+ if10% of cells expressed the ER.
The DBCG data provided recurrence information, defined as breast cancer—including
contralateral cancer—or distant metastases diagnosed after receipt of initial treatment. Because
tamoxifen reduces the rate of local, distant, and contralateral recurrences, these were grouped
under a global heading of”recurrence” for assessing the direct predictive effect of ApoD on
recurrence via the tamoxifen pathway. For the purposes of this study, a “case” was defined as a
recurrence that occurred within ten years of the initial diagnosis. Controls were free of recur-
rence at the time of matching, and were matched to cases on ER status, menopausal status,
stage, calendar time of diagnosis, and county.
Patients were also excluded if they had insufficient or invalid tissue material that could not
be scored on the tissue microarrays (TMAs). Invalid tissue included tumors that were non-
invasive, such as cores with only ductal carcinoma in situ, cores that were excessively over
stained, cores that were damaged or cores that were missing from the stained sections. In total,
371 patients were excluded because there was insufficient valid tissue for ApoD determination.
After these exclusions for quality control, 1,267 women remained in the study, each tumor
being represented by between one and four evaluable TMA cores.
Immunohistochemistry
Tissues were processed from formalin-fixed paraffin-embedded tissue blocks obtained from
pathology department archives using sterile protocols designed to avoid cross-contamination.
Cylindrical cores were sampled from each donor tumor and re-embedded into recipient TMA
paraffin blocks using standard procedures. TMAs were constructed using a TMA Master
(3DHistech Ltd., Budapest, Hungary) using 1 mm diameter cores. An asymmetrical design
was employed, using liver and placental tissue tissue cores as TMA orientation markers and as
controls. When possible, up to a maximum of three representative tumor cores and one mar-
ginal tissue core were sampled from each donor block (one block per patient), including a core
with normal tissue for quality control.
We used immunohistochemistry to determine the subcellular expression intensity and loca-
tion of ApoD. ApoD expression was detected using a rabbit monoclonal primary antibody at a
1:250 dilution, with thirty minutes of incubation time at room temperature (clone EPR2916,
Abcam, Cambridge, UK). We performed heat induced epitope retrieval using a target retrieval
solution with pH of 9. The visualization system used was Envision Flex, which uses 3,3’-diami-
nobenzidine as a chromogen and horseradish peroxidase as a labeled polymer. The stained
TMA sections were scanned at 40x magnification with the Hamamatsu Nanozoomer 2.0HT in
.ndpi format. Slides were converted with a beta version converter to conform to the 3DHistech
software and uploaded to Panoramic Viewer TMA Module software.
Scoring of TMA cores
Laboratory personnel, including scorers, were blinded to all clinical information, including
case or control status, ER status, and receipt of therapeutic agents. The stained TMA breast
carcinoma sections were read and scored for Apo-D expression by three observers (one experi-
enced pathologist (YH), and two trained students (DK and TJ)). Initially, 62 cores were inde-
pendently scored by the three raters, and agreement was compared for each rater pair. For
The role of ApoD in tamoxifen resistance
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ascertainment of positive cytoplasmic staining, agreement was generally good, with an average
concordance of 89%. Concordance of positive nuclear staining was lower, with 79% agreement
on average, although the total number of positively stained nuclei in the test sample was low,
leading to less precise measures of agreement. The pathologist reviewed all the TMA cores
after they were initially scored by the two other raters, to maximize scoring consistency. Dis-
cordantly scored cores were discussed by all three raters and a consensus score was agreed.
Cores were excluded if they were excessively torn, over-stained, or consisted exclusively of car-
cinoma in situ or normal tissue. If a combination of normal tissue and tumor was present,
only the portion with tumor was scored for ApoD.
Definitions of analytical variables
ApoD cytoplasmic staining. A semi-quantitative scoring system employing a histological
score, or “H-score,” was used for all analyses, as described by Soiland et al.[38] Briefly, the H-
score weights the proportion of tumor cells in each TMA core by the intensity of their staining
according to a four-level ordinal scale (0/negative, 1/weak, 2/moderate, or 3/strong). Soiland
et al. identified a threshold H-score of 0 as a significant cutoff for patients over seventy years
of age. Thus, patients with an H-score of zero were considered to have no ApoD expression,
while patients with an H-score >0 were considered to have ApoD present. Two variables were
used separately in the analysis—one dichotomous variable specifying staining as negative
versus positive, and one continuous variable with the H-score itself (1–300) to assess dose-
response (Fig 1a).
ApoD nuclear staining. Nuclear staining was quantified using a simplified nuclear N-
score, defined as the product between intensity of staining (1/light, 2/dark) and frequency of
staining (0/negative, 1/<25% positive nuclei, 2/25+ positive nuclei). Two variables were used
for this analysis as with cytoplasmic staining—one dichotomous (negative versus positive, cut-
off of 0), and one continuous (1–4) using the nuclear H-score (Fig 1b).
Fig 1. ApoD staining determinationζ §. §The source population consisted of 11,251 female residents of the
Jutland Peninsula in Denmark aged 35–69 years who were diagnosed with Stage I, II, or III breast cancer
between 1985 and 2001. ζ Brown signifies positive ApoD staining. A.Image depicts an
immunohistochemically stained TMA core that was scored for cytoplasmic ApoD by the three raters as
follows: 45% tumor cells weakly positive (1), 50% tumor cells moderately positive (2), and 5% tumor cells
strongly positive (3). B. Image depicts a TMA core with widespread, weak nuclear staining.
https://doi.org/10.1371/journal.pone.0171453.g001
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Statistical analysis
All statistical analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC). All analyses
were performed within strata of ER+/TAM+ and ER–/TAM– to isolate the association
between ApoD and recurrence. The ER–/TAM– group was included to examine any direct
prognostic effect of ApoD expression on recurrence. Crude frequencies were calculated within
the two strata showing the proportion of cases and controls in various categories of ApoD
staining, separated into nuclear and cytoplasmic staining. Conditional logistic regression was
used to calculate measures of association, with recurrence as the outcome and ApoD staining
status as the exposure variable. Odds ratios estimating the association of ApoD positivity in
the nucleus or cytoplasm with recurrence were computed, controlling for covariates. Matched
odds ratios (OR) were compared with those computed with additional adjustment for receipt
of chemotherapy, receipt of radiation therapy, and type of surgery. Within continuous catego-
rization of ApoD staining status, the OR was computed excluding the negative referent group
to assess the presence of a dose-response. We replicated analyses within strata of stage to
further assess the predictive value of ApoD. A probabilistic bias analysis was performed to
account for potential misclassification of ApoD staining, the results and methods of which are
presented in S1 File and S1 Table.
This study was approved by the Danish Data Protection Agency (journal number 2012-41-
1170) and the Ethical Committee (record number 1-10-72-16-15).
Results
Descriptive statistics
The majority of women were either Stage II (45%) or III (53%) at diagnosis, with only 2% des-
ignated as Stage I according to standards set by the Union for International Cancer Control.
[34] Approximately half of the women were between the ages of 55–64, with 24% in the 65–69
category, 22% in the 45–54 category, and only 3% of women between the ages of 35 and 44
years. Given the age distribution, only 6% of women were premenopausal (Table 1).
Approximately half of the ER+ tumor patients were initially assigned to two-year tamoxifen
treatment protocols according to the DBCG guidelines, with the remaining half split between
one- and five-year protocols. Medical records often indicated a longer tamoxifen protocol
compared to the registry, as patients likely were switched to the five-year protocol as evidence
emerged supporting longer adjuvant treatment.[37] As expected, a much greater percentage of
the ER– group was assigned to systemic chemotherapy treatment, as the overall prognosis for
this subset of breast cancer patients was lower, and fewer adjuvant treatment options existed.
In both the ER+ and ER– strata, the percentage of women with some positive cytoplasmic
ApoD expression was between 65% and 70%. Nuclear staining patterns differed somewhat
between ER strata, with approximately 39% of ER+ tumors exhibiting positive nuclear stain-
ing, compared with 25–30% of ER– tumors (Table 1).
Model results
In both the ER+/TAM+ and ER–/TAM– strata, all matched associations between ApoD and
breast cancer recurrence were near null in both the ER+/TAM+ and ER–/TAM– strata
(Table 2). For cytoplasmic staining, both dichotomous coding of ApoD staining (matched
OR = 1.0, 95% CI = 0.72, 1.39), as well as continuous coding assessing dose response (matched
OR = 1.0, 95% CI = 0.998, 1.002) resulted in null associations. Similarly, nuclear staining
also yielded near-null results both using dichotomous coding of ApoD staining (matched
OR = 1.0, 95% CI = 0.75, 1.38) and continuous coding (matched OR = 0.99, 95% CI = 0.83,
The role of ApoD in tamoxifen resistance
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Table 1. Frequency and proportion of breast cancer recurrence case patients and matched control subjects within group strata*.
Patient Characteristic ER+/TAM+, No.(%) ER-/TAM-, No.(%)
Recurrent Cases Controls Recurrent Cases Controls
Cytoplasmic ApoD Expression (H-Score)
= 0 135 (32) 144 (34) 80 (34) 77 (35)
>0 292 (68) 280 (66) 157 (66) 146 (66)
Missing † 114 117 63 77
Nuclear ApoD Expression (H-Score)
= 0 260 (61) 258 (61) 169 (71) 165 (74)
>0 167 (39) 166 (39) 68 (29) 58 (26)
Missing † 114 117 63 77
Joint ApoD Expressionζ
= 0 115 (44) 131 (46) 76 (54) 71 (58)
>0 147 (56) 153 (54 64 (46) 52 (42)
Missing † 279 257 160 177
Diagnosis Year§
1985–1993 235 (43) 234 (43.3) 107 (36) 100 (33)
1994–1996 113 (21) 112 (20.7) 81 (27) 83 (28)
1997–2001 193 (36) 195 (36) 112 (37) 117 (39)
Age category at diagnosis, yrs
35–44 13 (3) 12 (2.8) 52 (22) 41 (18)
45–54 92 (22) 86 (20) 94 (40) 84 (38)
55–64 221 (52) 222 (52) 67 (28) 68 (31)
65–69 101 (24) 104 (25) 24 (10) 30 (13)
Menopausal Status at diagnosis§
Premenopausal 34 (6.3) 34 (6.3) 121 (40) 121 (40)
Postmenopausal 507 (94) 507 (94) 179 (60) 179 (60)
UICC tumor stage at diagnosis§
I 8 (1.9) 6 (1.4) 14 (5.9) 15 (6.7)
II 194 (45) 193 (46) 128 (54) 115 (52)
III 225 (53) 225 (53) 95 (40) 93 (42)
Nodal involvement at diagnosis
0 33 (6.1) 39 (7.2) 82 (27) 110 (37)
1–3 240 (44) 251 (46) 101 (34) 76 (25)
4–9 177 (33) 196 (36) 76 (25) 84 (28)
10+ 91 (17) 55 (10) 41 (14) 30 (10)
Histological grade
I 108 (20) 144 (27) 27 (9.0) 23 (7.7)
II 234 (43) 215 (40) 125 (42) 98 (33)
III 92 (17) 57 (11) 103 (34) 106 (35)
IV 107 (20) 125 (23) 45 (15) 73 (24)
Missing
Surgery type
Breast-conserving surgery 383 (90) 368 (87) 199 (84) 181 (81)
Mastectomy 44 (10) 56 (13) 37 (16) 42 (19)
Missing 0 0 1 0
Radiation therapy
Yes 149 (35) 150 (35) 103 (44) 90 (47)
No 278 (65) 274 (65) 130 (56) 102 (53)
(Continued )
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Table 1. (Continued)
Patient Characteristic ER+/TAM+, No.(%) ER-/TAM-, No.(%)
Recurrent Cases Controls Recurrent Cases Controls
Missing 0 0 6 40
Tamoxifen protocol, yrs
1 257 (48) 261 (48)
2 98 (18) 92 (17)
5 186 (34) 188 (35)
Systemic adjuvant chemotherapy
Yes 53 (12) 42 (9.9) 203 (86) 139 (62)
No 374 (88) 382 (90) 34 (14) 84 (38)
Current ER expression
Positive 397 (93) 411 (97) 59 (25) 56 (25)
Negative 30 (7.0) 12 (2.8) 177 (75) 165 (74)
Not available† 0.0 1 (0.2) 1 (0.4) 2 (0.9)
*The source population consisted of 11,251 female residents of the Jutland Peninsula in Denmark aged 35–69 years who were diagnosed with Stage I, II,
or III breast cancer between 1985 and 2001. Subjects were estrogen receptor positive and received at least 1 year of tamoxifen therapy (ER+/TAM+) or ER
negative and never received tamoxifen therapy and survived at least 1 year after diagnosis (ER-/TAM-). ApoD = Apolipoprotein D; UICC = Union for
International Cancer Control.
†No tissue available for assay or assay results indeterminate
§Variable included in risk set sampling to match control subjects to case patients.
ζJoint effect indicates combined nuclear and cytoplasmic dichotomous staining
https://doi.org/10.1371/journal.pone.0171453.t001
Table 2. Associations between ApoD expression and breast cancer recurrence within strata*.
ApoD
Expression
ER+/TAM+ ER-/TAM-
Recurrent cases/
controls or mean§
Matched OR
(95% CI)†
Adjusted OR (95%
CI)‡
Recurrent cases/
controls or mean§
Matched OR (95%
CI)†
Adjusted OR
(95% CI)‡
Joint Expression
= 0 115/131 76/71
>0 147/153 0.87(0.55, 1.38) 1.14 (0.79, 1.65) 65/52 1.06 (0.54, 2.10) 1.29 (0.72, 2.32)
Cytoplasmic H-
score
= 0 135/144 80/77
>0 292/280 1.00 (0.72,1.39) 1.19 (0.83,1.50) 157/146 0.98 (0.64,1.49) 1.14 (0.74, 1.75)
Continuous Mean: 85.77/87.29 1.00 (0.996,
1.003)
1.00 (0.998,1.002) Mean: 90.9/108.4 1.00 (0.995,1.003) 1.00 (0.996,
1.001)
Nuclear H-score
= 0 260/258 169/165
>0 167/166 1.01 (0.74,1.38) 1.05 (0.78,1.40) 68/58 1.17 (0.71,1.92) 1.25 (0.79, 2.00)
Continuous Mean: 1.390/1.396 1.00 (0.65,1.55) 1.03 (0.88,1.21) Mean: 1.47/1.70 0.72 (0.38,1.37) 1.01 (0.80, 1.26)
*The source population consisted of 11,251 female residents of the Jutland Peninsula in Denmark aged 35–69 years who were diagnosed with Stage I, II,
or III breast cancer between 1985 and 2001. Subjects were estrogen receptor positive and received at least 1 year of tamoxifen therapy (ER+/TAM+) or ER
negative and never received tamoxifen therapy and survived at least 1 year after diagnosis (ER-/TAM-). ApoD = Apolipoprotein D; UICC = Union for
International Cancer Control.
†Estimated using logistic regression; case patients were matched to controls on ER status, menopausal status, stage, calendar time of diagnosis, and
county
‡Estimated using logistic regression with adjustment for time to recurrence or control selection, menopausal status, stage, receipt of chemotherapy, receipt
of radiation therapy, and type of surgery.
§Mean for cases/controls provided for continuous variable, whereas frequency is provided for cases/controls for dichotomous exposure variable
https://doi.org/10.1371/journal.pone.0171453.t002
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1.18). The ER–/TAM– group also yielded near null associations that were almost identical to
those in the ER+/TAM+ group. The associations estimating the effect of joint nuclear and
cytoplasmic expression on recurrence were also near-null in both the ER+ stratum (matched
OR = 0.87, 95% CI = 0.55, 1.38) and the ER– stratum (matched OR = 1.06, 95% CI = 0.54, 2.1).
Associations were similarly null among women of all stages when examined separately (S2
Table)
Discussion
In spite of plausible biological hypotheses and the results of earlier studies, we did not observe
an association between tumor ApoD expression and recurrence among ER+, tamoxifen-
treated patients. The effect was near null in all categories of ApoD localization—nuclear, cyto-
plasmic or both—and in both dichotomous and continuous categorizations of staining. Asso-
ciations were near null among ER+ tumor patients and ER– tumor patients, with indiscernible
differences in estimates between the two groups. This further suggests that ApoD positivity in
ER+ patients is not reflective of a malfunctioning tamoxifen pathway, as any effect dependent
upon the estrogen-tamoxifen pathway would be confined to the ER+ group.
This study is the largest yet investigating the association between ApoD expression and
recurrence (80% power to detect a 1.5-fold change in recurrence), and resulted in precise and
null estimates. Selection bias was likely avoided in the design phase, as all cases and controls
were selected from the DBCG registry, which contains nearly all Danish breast cancer cases
under the age of 70 at diagnosis.[33]
Tamoxifen therapy duration was often inconsistent between the DBCG registry and the
patients’ medical records, with the registry indicating that the patient was assigned a shorter
duration of therapy. These patients were likely initially assigned the one- or two-year protocol,
and then switched to longer protocols as evidence in favor of the five-year protocol became
more widespread.[37] Since patients were likely to be on tamoxifen for longer periods of time
than the registry indicated, their recurrences were less likely to result from short duration
therapy.
There was good concordance between ER+ status at diagnosis and upon re-assay.[39] A
previous validation study using medical record review confirmed all recurrences, eliminating
the potential for outcome misclassification, and showed perfect agreement for all covariates
except one patient’s menopausal status.[40] Staining guidelines were designed to be clinically
applicable to ensure that ApoD could be a practical predictive or prognostic indicator if an
association was found.
In certain strata, such as for assessing the joint effect of nuclear and cytoplasmic staining,
the sample size was fairly small. However, given the consistency of precise null results in nearly
all categories of staining, it is unlikely that these estimates would change meaningfully with an
increased sample size.
As with many other predictive immunohistochemical biomarkers, the threshhold expres-
sion levels to be used to discriminate between ApoD positive and negative cases remain to be
established. There is insufficient information to designate such a cutoff for ApoD, but results
were null when assessed using dichotomous categorization, as well as dose-response continu-
ous coding among non-zero cores.
Earlier studies that demonstrated an association between ApoD and recurrence did so only
within age-specific strata, and had smaller sample sizes.[26, 32] In order for ApoD to be prog-
nostically relevant, it must be meaningfully associated with recurrence in largely nonspecific
groups, or its stratum-specific associations must be meaningfully different. A key earlier study
in particular found a potential association between ApoD and disease-specific survival in
The role of ApoD in tamoxifen resistance
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elderly, comorbid patients not receiving chemotherapy.[38] Our results are near null and simi-
lar across biologically relevant groups, suggesting that the true association between ApoD
expression and recurrence is likely null. As such, the need remains for predictors of response
to tamoxifen, as well as recurrence following completion of adjuvant treatment, in order to
assess the need for longer duration of therapy or alternate treatments.
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S1 Table. Bias-adjusted estimates using probabilistic methods with varying distributions.
Adjusted estimates were calculated using summary-level 2x2 tables containing exposure and
outcome data using an excel spreadsheet created by Lash, Fox, and Fink3 †Value calculated
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ative bias-adjusted cell values.
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S2 Table. Matched associations between ApoD expression and breast cancer recurrence
within strata of ER status and stage. The source population consisted of 11,251 female res-
idents of the Jutland Peninsula in Denmark aged 35–69 years who were diagnosed with
Stage I, II, or III breast cancer between 1985 and 2001. Subjects were estrogen receptor posi-
tive and received at least 1 year of tamoxifen therapy (ER+/TAM+) or ER negative and
never received tamoxifen therapy and survived at least 1 year after diagnosis (ER-/TAM-).
ApoD = Apolipoprotein D; UICC = Union for International Cancer Control. †Estimated
using logistic regression; case patients were matched to controls on ER status, menopausal
status, stage, calendar time of diagnosis, and county NC = Model convergence not satisfied
due to sample size limitations within certain strata §Over-inflated variance due to sample
size limitations within certain strata.
(PDF)
S1 File. Quantitative bias analysis.
(PDF)
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